
Using weight loss jabs could increase the risk of developing “severe” gastrointestinal problems, according to a study.
US researchers said semaglutide, marketed as Wegovy or Ozempic, could heighten the probability of pancreatitis, bowel obstructions and “stomach paralysis” in non-diabetics.